Full-Time
Operations Training Specialist
Posted on 11/23/2025
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Bethlehem, PA, USA
In Person
Willing to travel up to 20%.
 Operations & Logistics (2) |
|---|
| , |
- Completion of a four-year bachelor's degree and five years’ experience or an equivalent combination of experience and education.
- Successful candidates will possess strong data analytic skills and the ability to successfully deliver training materials to new hires, cross training functions, leadership level positions, and to associates that need to improve performance.
- Strong data analytic skills and the ability to successfully deliver training materials to new hires, cross training functions, leadership level positions, and to associates that need to improve performance.
- Proficiency with remote meeting technologies and demonstrated knowledge of software technology.
- Ability to review and interpret data and adjust as appropriate.
- Excellent communication skills, both orally and in writing.
- Ability to participate and contribute to major organizational change initiatives.
- Excellent problem-solving skills and the ability to resolve issues effectively and efficiently.
- Ability to train others and establish learning objectives in a fast-paced and changing environment.
- Effective teambuilding, organizational, and leadership skills.
- Strong presentation skills.
- Knowledge of Labor Management Systems and Standard Operating Procedures preferred.
- Experience with Learning Management Systems preferred.
- Familiarity with warehouse operations software and inventory systems preferred.
- Up to 20% travel.
- Must be willing to work extended hours, as needed, to meet training objectives.
- Delivers training programs for associates, including compliance, safety, specific job function training and related Standard Operating Procedures (SOP).
- Oversees training in all key areas of warehouse operations, including shipping, receiving, quality control, pick, pack, inventory management systems.
- Determines training needs and communicates them to their manager and assists with the development of training aids such as instructional materials, handouts, evaluation forms, and visual aids, using a variety of media through contributions as a subject matter expert.
- Gather content and design low complexity materials, meet timeline deliverables and deadlines, and communicate risks to project manager/lead in a timely manner as a subject-matter expert.
- Recommends changes to course material and training manuals to meet specific training needs.
- Participate in the testing and piloting of new training programs and provide valuable feedback to ensure successful future training deployment initiatives.
- Assesses associates’ skills, talents, performance and productivity, prepare evaluations and make recommendations for improvement.
- Onboard new hires and manage training curriculum, identify skill gaps, identify future training needs.
- Administers post-training performance evaluations and makes recommendations.
- Consistently implements measurement strategies.
- Keeps current on industry needs by attending regular meetings, conferences, and seminars.
- Maintains understanding of new educational and training methodology.
- Performs related duties as assigned.
- Training experience is highly preferred.
- Warehouse experience desirable.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Simplify's Take
What believers are saying
- Specialty pharmaceuticals remain the main growth engine for higher-margin services.
- Management targets $300 million in savings while sustaining about $3 billion free cash flow.
- Share repurchases and accretive acquisitions can support earnings per share.
What critics are saying
- Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
- Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
- Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.
What makes Cencora unique
- Cencora combines drug distribution, specialty pharmacy, and patient-support services.
- It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
- The company is expanding specialty care through OneOncology and EyeSouth retina assets.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Cencora who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.
Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.
Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.
Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.
Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.